Merck KGaA to Acquire SpringWorks Therapeutics After Negotiations
Merck KGaA announced its intention to acquire SpringWorks Therapeutics following several months of negotiations. The announcement confirms the completion of a deal that will see SpringWorks Therapeutics become part of Merck KGaA. The acquisition comes after extensive discussions between the two companies. The agreement signifies a strategic move by Merck KGaA to expand its portfolio through the acquisition of SpringWorks Therapeutics and their related assets. The specific details of the deal, including financial terms, were not disclosed in the announcement.
Newsflash | Powered by GeneOnline AI
Date: April 28, 2025
LATEST
A Look at Taiwan-German Collaborative Solutions in Precision Medicine, Drug Development, and Medical Tech
2025-05-21
ACOG Updates Pain Management Guidelines for IUD Insertions as Novavax Vaccine Gains Approval
2025-05-20
UnitedHealth Group Stock Drops Amid Rising Medicare Advantage Costs and Regulatory Debates
2025-05-20